Open AccessIs there variability in drug release and physical characteristics of amiodarone chloride from different commercially available tablets? Possible therapeutic implications
Author(s) -
Ngo Suong N.T.,
Barnes Timothy
Publication year - 2010
Publication title -
international journal of pharmacy practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.42
H-Index - 37
eISSN - 2042-7174
pISSN - 0961-7671
DOI - 10.1111/j.2042-7174.2010.00037.x
Subject(s) - bioavailability , dissolution , friability , bioequivalence , medicine , drug , innovator , amiodarone , pharmacology , dissolution testing , chromatography , chemistry , biopharmaceutics classification system , organic chemistry , first pass effect , intellectual property , computer science , atrial fibrillation , operating system
Objectives Amiodarone is a low‐solubility, high‐permeability drug with a narrow therapeutic index and reported bioavailability problems associated with switching formulations. The aim of this study was to identify whether there is variability in drug release and physical characteristics of different commercially available amiodarone hydrochloride formulations in Australia. Methods Four available formulations (innovator Cordarone (COR) and generic products G1, G2 and G3) were tested for drug dissolution, content uniformity, hardness, weight variation, friability and disintegration in accordance with the US Pharmacopeia specifications. Key findings The tested formulations exhibited variable dissolution behaviours: G1 and G3 exhibited the fastest dissolution, G2 dissolution was the slowest and Cordarone showed a medium dissolution. After 3 months' exposure to high temperature (40 ± 2°C) and relative humidity (75 ± 5%), the products exhibited a higher degree of disparity, with drug‐release profiles of the generics being markedly different from that of Cordarone. This suggests possible implications on bioequivalence for patients who live in warm/tropical regional areas. Most products met the US Pharmacopeia specifications for drug‐content uniformity and other test physical characteristics. Conclusions The results suggested that variability in drug release profiles in vitro of amiodarone formulations might be a potential indicator of compromised bioavailability, causing possible interference with the therapeutic response of the drug.